Covered Companies: CNS Pharmaceuticals
Most Recent Event
What This Means
June 8, 2026
Steve O’Loughlin, Chief Financial Officer of CNS
Pharmaceuticals, discusses the Company’s recently completed oversubscribed $22.5 million financing, addressing the factors that enabled the successful capital raise following its strategic reset and acquisition-focused transformation.
CNS Pharmaceuticals is a biotechnology company focused on developing innovative therapies for serious diseases.
NASDAQ: CNSP
About
CNS Pharmaceuticals is a biotechnology company focused on developing innovative therapies for serious diseases. With an experienced executive team and a focus on high-value therapeutic opportunities, the Company is working to build a differentiated portfolio of assets addressing significant unmet medical needs. CNS is committed to advancing novel treatments that have the potential to improve patient outcomes while creating long-term value for patients and shareholders.
Past Events
CEO Connect
May 20, 2026
Rami Levin, President and Chief Executive Officer of CNS Pharmaceuticals, highlighted the Company’s recent $22.5 million financing, including its strategic pivot, progress made to date and how the capital positions CNS to identify and advance new assets aimed at driving long-term shareholder value.
